AstraZeneca's Imfinzi (Durvalumab) And Lynparza (Olaparib) Have Been Recommended For Approval In The European Union As Treatment For Certain Patients With Primary Advanced Or Recurrent Endometrial Cancer

Benzinga · 07/01 10:04
  • Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been recommended for patients with mismatch repair proficient (pMMR) disease.
  • Imfinzi plus chemotherapy followed by Imfinzi alone has been recommended for patients with mismatch repair deficient (dMMR) disease.